BRISTOL, Tenn.--(BUSINESS WIRE)--July 18, 2006--King Pharmaceuticals, Inc. (NYSE: KG - News) announced today that the U.S. District Court for the Eastern District of Virginia, Norfolk Division, upheld the validity of U.S. Patent No. 5,061,722 (the "722 patent"), the composition of matter patent covering Altace® (ramipril). Previously, on June 5, 2006 the Court granted summary judgment in favor of King finding that Lupin Ltd.'s proposed generic product infringed King's 722 patent. Also, on June 14, 2006, during the course of trial, the Court found the 722 patent enforceable, dismissing Lupin's unenforceability claims as a matter of law.
